Status:

COMPLETED

Feasibility of Slow Continuous UltraFiltration For Deresuscitation in Critically Ill Patients

Lead Sponsor:

Belfast Health and Social Care Trust

Conditions:

Fluid Overload

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To determine the feasibility and safety of deresuscitation using slow continuous ultrafiltration with regional citrate anticoagulation and peripheral or standard central venous access.

Detailed Description

Fluid deresuscitation has been shown to have favourable outcomes in the management of the critically ill patient. Whilst diuretic medications have previously been the mainstay of achieving this deresu...

Eligibility Criteria

Inclusion

  • Adults (\>18 years)
  • Evidence of fluid overload (greater than trace amount of peripheral oedema in \>1 site, pulmonary oedema on chest radiograph, or positive fluid balance equivalent to \>5% body weight)
  • Clinician intention to target a negative fluid balance
  • Expected to remain in a critical care setting beyond the next calendar day

Exclusion

  • Anticipated unavailability of suitable vascular access
  • Lack of commitment to full support
  • Receiving or imminently planned to receive renal replacement therapy
  • Hyponatraemia (Sodium \<130mmol/L)
  • Hypernatraemia (Sodium \>150mmol/L)
  • Significant metabolic alkalosis (Bicarbonate\>30 and pH\>7.5)
  • Significant metabolic acidosis (HCO3- \<18 mmol/l and pH \< 7.30)
  • Uncorrected hypokalaemia (Potassium \<3.0mmol/L)
  • Liver failure (Child-Pugh Grade B or above)
  • Shock (any of: lactate \>3mmol/L, extensive skin mottling, central capillary refill time\>3 seconds, more than 1 vasoactive agent in use, noradrenaline dose \>0.2 mcg/kg/min, use of dobutamine, adrenaline, milrinone, enoximone or levosimendan)
  • Receiving any systemic anticoagulation other than for routine venous thromboembolism prophylaxis, or dual antiplatelet therapy
  • Prisoner
  • Known pregnancy

Key Trial Info

Start Date :

August 12 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2024

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT05431491

Start Date

August 12 2022

End Date

December 1 2024

Last Update

May 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Belfast City Hospital

Belfast, Down, United Kingdom, BT97AB